Girl Planting seeds

Bayer Needs More Than an Aspirin to Cure Its Monsanto-Sized Headache

In a special telephone meeting on Thursday, August 23, Bayer AG’s CEO Werner Bauman tried to reassure the German conglomerate’s principal shareholders who were concerned about the recent drop in the company’s stock. Bayer’s stock fell dramatically after an unfavorable verdict against Bayer’s St. Louis subsidiary, Monsanto.  Bauman expressed his confidence in Monsanto and predicted a sunny future for its flagship herbicide, Roundup.  He told his top-tier investors that Bayer had performed an adequate due-diligence on Monsanto before purchasing the troubled company for $66 billion this past June. At the time of its purchase, Monsanto told its German suitors that a $270-million set-aside would cover all its outstanding liabilities arising from Monsanto’s 5,000 Roundup cancer lawsuits.  Bauman did concede to anxious shareholders that Monsanto had withheld internal papers relevant to the case. Bayer never saw those internal Monsanto documents prior to the purchase.  Read more...
 

 

Back

 
 
close (X)